The pathogenesis of neuroinvasion in Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies following the peripheral uptake of a disease agent is still not fully understood. The possibility of neuroinvasion either being established or being accelerated by an insult to the brain has not previously been tested. The experiment described herein was designed to examine this possibility by wounding the brain following an intraperitoneal challenge with a mouse-adapted strain of human transmissible spongiform encephalopathy, Fukuoka-1 strain. The results showed that brain injury introduced in any period before the appearance of cerebral abnormal prion protein deposition modified neither the clinical features, including the incubation period, nor the histopathology of the mice. Our findings suggest that neurovirulence of the agent may not be sufficiently promoted by brain injury.
The pathogenesis of neuroinvasion in Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies following the peripheral uptake of a disease agent is still not fully understood. The possibility of neuroinvasion either being established or being accelerated by an insult to the brain has not previously been tested. The experiment described herein was designed to examine this possibility by wounding the brain following an intraperitoneal challenge with a mouse-adapted strain of human transmissible spongiform encephalopathy, Fukuoka-1 strain. The results showed that brain injury introduced in any period before the appearance of cerebral abnormal prion protein deposition modified neither the clinical features, including the incubation period, nor the histopathology of the mice. Our findings suggest that neurovirulence of the agent may not be sufficiently promoted by brain injury.
Creutzfeldt-Jakob disease (CJD) is one type of human fatal transmissible spongiform encephalopathy (TSE) caused by an agent similar to those involved in scrapie, bovine spongiform encephalopathy (BSE) and transmissible mink encephalopathy. Pathological changes are limited to the central nervous system, but infectivity is demonstrated not only through the central nervous system but also through various extraneural tissues in experimental animals (Eklund et al., 1967 ; Asher et al., 1976 ; Gibbs et al., 1978 ; Tateishi et al., 1980 b ; Kuroda et al., 1983) . After the introduction of the agent through such peripheral routes as the intraperitoneal, intravenous, percutaneous and peroral routes, infectivity first appears in the lymphoreticular system and then in the brain. Previous studies suggest that infection enters the central nervous system either at the Author for correspondence : Katsumi Doh-ura.
Fax j81 92 642 5540. e-mail doh-ura!np.med.kyushu-u.ac.jp thoracic spinal cord (Kimberlin & Walker, 1979 , 1986 or at the brain stem along the vagus nerve after a peripheral challenge of the agent in small rodents (Beekes et al., 1998) . It has recently been reported that differentiated B-lymphocytes are essential for neuroinvasion (Klein et al., 1997) . Transmissibility through the transfusion of blood or blood products in humans remains a controversial topic (Esmonde et al., 1993 ; Menache & O'Malley, 1996 ; Ricketts et al., 1997 ; Brown et al., 1998) , but infectivity was reported to be present in the circulating blood during both the preclinical and clinical stages in experimental animals (Kuroda et al., 1993 ; Casaccia et al., 1989) . Based on these findings within the context of the blood-brain barrier (BBB) dysfunction reported in the affected animals (Wisniewski et al., 1983 ; Chung et al., 1995 ; Vorbrodt et al., 1997) , an alternative possible route of entry to the brain might also be through the blood stream, especially in cases of impaired BBB integrity, which may occur even temporarily in elderly humans. In fact, sporadic CJD occurs predominantly in the elderly.
On the other hand, outbreaks of CJD in younger people who have had neurosurgical manipulation including cadaveric dura grafting have been reported, and have become a matter of great public concern especially in Japan (Anon., 1997) . These cases are proposed to result from surgical materials contaminated with TSE agents. Experimentally, however, this has not been proven in most cases, with a few exceptions . It is possible that temporary brain injury accompanied by neurosurgical procedures may accelerate the neurovirulence of this agent and thereby hasten the disease onset in individuals already infected through a peripheral route, while not being related to the infectivity status in the peripheral blood. There have so far been no reports on the potential for neuroinvasion to be established through an impaired BBB integrity or to be accelerated by brain injury. This study was thus undertaken to examine these possibilities in mice challenged with a mouse-adapted strain of the human TSE agent.
The murine Fukuoka-1 strain (Fu-1) was used for the experiment. This strain is derived from a patient with 
Gerstmann-Stra$ ussler-Scheinker syndrome and was obtained from the fourth passage in NZW\Sea mice. First, we examined the sequence of the lesions in intraperitoneally (i.p.) inoculated mice by tracing the deposition of the disease-specific prion protein (PrP) (Prusiner, 1991) . Weaning female NZW\Sea mice were i.p.-inoculated with 100 µl of 1 % Fu-1-infected brain homogenate and they were then sacrificed under ether anaesthesia in triplicate at 2-or 4-week intervals until the terminal stage. The brain was immediately removed and fixed in 4 % buffered paraformaldehyde solution. Paraffin sections (5 µm) of the brain were stained with haematoxylin and eosin or by immunohistochemistry for abnormal PrP with antiserum PrP-N (Kitamoto et al., 1991 a) as previously described (Kitamoto et al., 1992) . As a result, abnormal PrP depositions in the spleen and in the brain were demonstrated at 8 to 10 weeks and at 16 to 20 weeks after i.p. inoculation, respectively. The depositions persistently increased in intensity and distribution in the brain until death or extreme stage (around 34 weeks post-i.p. inoculation). In the spleen they were observed in follicular dendritic cells as described previously (Kitamoto et al., 1991 b ; Fraser et al., 1992) . In the brain, they first appeared in the neuropil of the thalamus, and spread to the whole brain throughout the illness. Based on these findings, brain injury was introduced in each group of five to seven i.p.-inoculated mice by intracerebrally (i.c.) injecting 20 µl of either saline, 1 % normal brain homogenate or 1 % Fu-1-infected brain homogenate at 0, 4, 8, 12 or 16 weeks post-i.p. inoculation. The mice were examined three times a week for clinical assessment of the illness. The mean incubation period was calculated as the interval from inoculation to death or extreme stage. The incubation periods in both the i.p.-inoculated control mice and i.c.-inoculated control mice were 242 days and 127 days, respectively. As shown in Table 1 , the incubation periods in the i.p.-inoculated mice with brain injury on day 0, by injecting either saline or 1 % normal brain homogenate, were a little shorter than the control, by 19 days (P 0n05) or by 23 days (P 0n01), respectively. With these exceptions, the incubation periods in the mice subjected to an injection of either saline or 1 % normal brain homogenate were all around 240 days and showed no significant changes from the control. In addition, the i.p.-inoculated mice subsequently i.c.-injected with Fu-1 homogenate showed an almost constant incubation interval, around 127 days, from i.c. injection to death, irrespective of the preincubation interval after i.p. inoculation.
Both i.p.-inoculated mice and i.c.-inoculated mice exhibited signs of the disease, such as reduced vividness, ruffled fur, weight loss, arched back, generalized tremors, tail rigidity, bradykinesia, paraplegia in the hind legs and uncoordinated movements. These disorders progressed rapidly and the mice died within 2 weeks after the onset of the illness. The i.p.-inoculated mice tended to show paraplegia in the hind legs and uncoordinated movements first, while the clinical signs in the i.c.-inoculated mice began with reduced vividness and ruffled fur. Every i.p.-inoculated mouse with a subsequent i.c. injection of saline or normal homogenate showed clinical signs and Effect of brain injury on i.p.-inoculated TSE Effect of brain injury on i.p.-inoculated TSE disease progression that were indistinguishable from those of the i.p.-inoculated control. In the i.p.-inoculated mice subsequently i.c.-injected with Fu-1 homogenate, the clinical manifestations and disease course were similar to those of the i.c.-inoculated control. These findings indicate that not only the incubation period but also the clinical features were uninfluenced by the brain injury introduced in the i.p.-inoculated mice at any time before the appearance of brain PrP deposition. In addition, an i.c. infection was also suggested to be exclusive and not modified due to pre-incubation by i.p. infection.
To confirm these results, the mice were histopathologically evaluated in duplicate at 20 weeks post-i.p. inoculation or in the terminal stage by the presence of vacuolation and PrP deposition. The severity of vacuolation and the intensity of PrP deposition were scored in nine brain regions in the contralateral hemisphere of the injected site (Table 2 ). In i.p.-inoculated control mice, abnormal PrP deposition at an early stage was noted in the thalamus (20 weeks post-i.p. inoculation in Table 2 and Fig. 1 a) and additionally in the internal capsule in some mice, and the lesions became intense in all brain regions, especially in the pons and cerebellar deep white matter at the terminal stage. On the other hand, the i.c.-inoculated control mice at an early stage showed an overt lesion not only in the thalamus but also in the cerebral white matter between the cortex and hippocampus (8 weeks post-i.c. inoculation in Table 2 and Fig. 1 b) , while lesions at an advanced stage showed similarly intense findings in the pons and cerebellar deep white matter, but they were more intense in the other brain regions than those of the i.p.-inoculated mice. In the model we used herein, the pathological difference observed at an early stage in the mice subjected to i.p. inoculation or i.c. inoculation was the intensity of the lesions in the cerebral white matter between the cortex and hippocampus. In mouse models of scrapie or BSE the brain pathology has been reported to be milder after i.p. infection than after i.c. infection (Fraser, 1976 ; Lasme! zas et al., 1996) . The TSE model we used fulfilled this criterion. The histopathological findings were almost completely constant in the i.p.-inoculated mice subsequently i.c.-injected with either saline or normal brain homogenate, irrespective of the time of the injection, even in the i.p.-inoculated mice with brain injury on day 0, which exhibited slightly shorter incubation periods. Thus, the results of the i.p.-inoculated mice i.c.-injected at 12 weeks post-i.p. inoculation were presented as representative data of the histopathological findings in Table 2 . The severity and distribution of the brain pathology in all the i.p.-inoculated mice i.c.-injected with either saline or normal brain homogenate were almost identical to those seen with the i.p.-inoculated control (Table 2 and Fig. 1  c) . In addition, the i.p.-inoculated mice subsequently i.c.-injected with Fu-1 homogenate showed different brain pathology to the i.p.-inoculated control, but showed almost the same pathology as the i.c.-inoculated control (Table 2 and Fig. 1 d) . Since the incubation periods of the i.p.-inoculated mice with subsequent i.c. injection of Fu-1 homogenate at 16 weeks were almost the same as those of the i.p.-inoculated control mice, they were expected to be able to exhibit either the phenotype of i.c. infection or i.p. infection. All of them, however, showed the phenotype of i.c. infection. The i.p. infection phenotype seemed to be masked by i.c. infection, because the i.c. infection phenotype shows a more severe intensity and distribution of neurodegeneration. The results described in the incubation period and clinical features were further confirmed by the histopathological findings.
In this report, we did not show infectivity of the peripheral blood in mice i.p.-inoculated with the Fu-1 strain, but this is the same strain that was used for the experiments by Kuroda et al. (1983) , in which the infectivity in the circulating blood was demonstrated both in the preclinical stage and the clinical stage in the mice. The results described herein thus suggest that neuroinvasion is not caused via the blood stream by a temporary impairment of the BBB integrity. However, we should not rush to a conclusion. In the murine model of noninflammatory spongiform neurodegenerative disease by a neurovirulent retrovirus FrCasE, the resistance of the brain to infection lies at the BBB integrity and is bypassed not by focal brain injury within susceptible brain regions, but by a direct introduction into the brain of virus-infected microglial cells (Lynch et al., 1995) . This might also be true of our TSE model. Following brain injury a profound inflammatory response is immediately initiated, which is characterized by the release of several cytokines such as IL-1β, TNF-α and TGF-β1 with proand anti-inflammatory functions (Morganti-Kossman et al., 1997 ; Ghirnikar et al., 1998) . Such cytokines induce severalfold increases in normal PrP expression in neural cell lines (Satoh et al., 1998) , and normal PrP overexpression always accelerates the disease onset in transgenic models (Prusiner, 1991) . Recently one such cytokine, TGF-β1, was suggested to initiate or promote amyloidogenesis of β-amyloid precursor protein in Alzheimer's disease and in experimental models (Wyss-Coray et al., 1997) , while another cytokine, IL-1β has a stimulatory influence on the generation of the amyloidogenic β-amyloid precursor protein metabolite in thyroid cells (Schmitt et al., 1996) . In light of these findings, the presence of such cytokines might result in promoting a production of PrP amyloid. In fact, in the murine scrapie model, such cytokines occur only in those brain areas showing PrP depositions, and Effect of brain injury on i.p.-inoculated TSE Effect of brain injury on i.p.-inoculated TSE PrP deposition has been suggested to induce the production of such cytokines and contribute to the development of pathological lesions (Williams et al., 1997) . As a result, a vicious cycle might exist, where abnormal PrP deposition and cytokine production occur in succession. In the present study, however, local cytokine induction by brain injury did not modify the clinical features or neuropathology. This suggests that local brain injury might be insufficient to start this vicious cycle.
In conclusion, a murine TSE model was used to examine the effects of brain injury on the neurovirulence of peripherally infected TSE. The incubation period, clinical features and histopathology in i.p.-infected mice were not modified by the local brain injury introduced at any time before the appearance of cerebral PrP deposition. This suggests that neuroinvasion might not be caused by an impaired BBB alone, and also may not be promoted by local brain injury.
